HomeCompareTRHC vs PFE

TRHC vs PFE: Dividend Comparison 2026

TRHC yields 19.05% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRHC wins by $19.3K in total portfolio value
10 years
TRHC
TRHC
● Live price
19.05%
Share price
$10.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.9K
Annual income
$6,079.53
Full TRHC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TRHC vs PFE

📍 TRHC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRHCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRHC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRHC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRHC
Annual income on $10K today (after 15% tax)
$1,619.05/yr
After 10yr DRIP, annual income (after tax)
$5,167.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $17,152.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRHC + PFE for your $10,000?

TRHC: 50%PFE: 50%
100% PFE50/50100% TRHC
Portfolio after 10yr
$59.2K
Annual income
$16,169.13/yr
Blended yield
27.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TRHC
Analyst Ratings
1
Strong
11
Buy
8
Hold
Consensus: Buy
Price Target
$3.00
-71.4% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.7
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRHC buys
0
PFE buys
0
No recent congressional trades found for TRHC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRHCPFE
Forward yield19.05%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$68.9K$49.6K
Annual income after 10y$6,079.53$26,258.71
Total dividends collected$38.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$3.00$27.50

Year-by-year: TRHC vs PFE ($10,000, DRIP)

YearTRHC PortfolioTRHC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,605$1,904.76$9,153$693.39+$3.5KTRHC
2$15,731$2,243.84$8,593$849.25+$7.1KTRHC
3$19,449$2,617.14$8,336$1,066.78+$11.1KTRHC
4$23,835$3,024.07$8,437$1,384.80+$15.4KTRHC
5$28,967$3,463.51$9,013$1,875.40+$20.0KTRHC
6$34,928$3,933.88$10,306$2,680.72+$24.6KTRHC
7$41,806$4,433.18$12,820$4,101.38+$29.0KTRHC
8$49,692$4,959.03$17,673$6,826.70+$32.0KTRHC
9$58,679$5,508.79$27,543$12,591.86+$31.1KTRHC
10$68,866$6,079.53$49,560$26,258.71+$19.3KTRHC

TRHC vs PFE: Complete Analysis 2026

TRHCStock

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization; and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. Further, the company provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2021, it served approximately 150 healthcare organizations; and 350 health plans and approximately 18,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.

Full TRHC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TRHC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRHC vs SCHDTRHC vs JEPITRHC vs OTRHC vs KOTRHC vs MAINTRHC vs JNJTRHC vs MRKTRHC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.